Sarcomatrix, Inc. Press Releases - EIN Presswire - Press Release Distribution Service

Published on July 24, 2026 - 08:32 GMT

Sarcomatrix Therapeutics Opens Accredited Investor Round for Once-Daily Pill to Address Duchenne Across Genetic Mutation

Sarcomatrix opens its accredited investor round to advance S-969, a once-daily, mutation-agnostic oral therapy for Duchenne toward human trials. RENO, NV, UNITED STATES, July 24, 2026 /⁨EINPresswire.com⁩/ -- FOR IMMEDIATE RELEASE Sarcomatrix …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on July 15, 2026 - 21:18 GMT

Sarcomatrix Therapeutics Corp. Opens Seed+ Investment Round to Accredited Investors on the KoreInside Platform

Preclinical-stage Nevada biotech funds its oral, mutation-agnostic Duchenne muscular dystrophy program toward a 2027 IND filing and first-in-human dosing. RENO, NV, UNITED STATES, July 15, 2026 /⁨EINPresswire.com⁩/ -- Sarcomatrix Therapeutics Corp., a …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on April 22, 2025 - 14:15 GMT

Sarcomatrix Therapeutics Launches Regulation D Offering to Advance Novel Oral Muscle Disease Therapy

Proceeds to support IND preparation and first-in-human studies targeting muscle-wasting diseases RENO, NV, UNITED STATES, April 22, 2025 /⁨EINPresswire.com⁩/ -- Sarcomatrix Therapeutics, a privately held biotechnology company developing first-in-class …

Distribution channels: Companies, Conferences & Trade Fairs ...

Published on April 9, 2025 - 23:55 GMT

Sarcomatrix Renews United States Orphan Drug Designation for LAMA2-Related Muscular Dystrophy Program

RENO, NV, UNITED STATES, April 9, 2025 /⁨EINPresswire.com⁩/ -- Sarcomatrix Therapeutics, a privately held biopharmaceutical company advancing transformative therapies for severe muscle diseases, today announced the renewal of its Orphan Drug Designation ( …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on March 12, 2025 - 16:00 GMT

Sarcomatrix to Present Preclinical Data on S969 for Duchenne Muscular Dystrophy at MDA Clinical & Scientific Conference

RENO, NV, UNITED STATES, March 12, 2025 /⁨EINPresswire.com⁩/ -- Sarcomatrix Therapeutics, a biopharmaceutical company developing novel treatments for muscle diseases, will present new preclinical data on its lead drug candidate, S969, at the Muscular …

Distribution channels: Conferences & Trade Fairs, Education ...

Published on March 11, 2025 - 13:36 GMT

Sarcomatrix Therapeutics Announces Strategic Collaboration with RNA Advisors to Advance Drug Development Strategy

RENO, NV, UNITED STATES, March 11, 2025 /⁨EINPresswire.com⁩/ -- Sarcomatrix Therapeutics, a biopharmaceutical company pioneering novel treatments for muscular dystrophies and age-related muscle degeneration, today announced a strategic collaboration with …

Distribution channels: Banking, Finance & Investment Industry, Conferences & Trade Fairs ...

Published on January 23, 2025 - 23:54 GMT

Sarcomatrix Joins Biotechnology Innovation Organization to Drive Breakthroughs in Muscle Disease Therapies

RENO, NV, UNITED STATES, January 23, 2025 /⁨EINPresswire.com⁩/ -- Sarcomatrix Therapeutics, a pioneering biotechnology company dedicated to developing innovative therapies for muscle diseases and rare conditions, proudly announces its membership in the …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on January 7, 2025 - 14:00 GMT

Sarcomatrix Therapeutics and Celito Tech Announce Strategic Collaboration to Advance S-969 to the Clinic

Optimizing CMC and Clinical Operations with cutting edge technology. RENO, NV, UNITED STATES, January 7, 2025 /⁨EINPresswire.com⁩/ -- January 7, 2025 — Sarcomatrix Therapeutics, a biotech innovator in muscle disease therapies, today announced a strategic …

Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...

Published on January 6, 2025 - 19:50 GMT

Sarcomatrix to Present at Three Major Events During JPM Week 2025 in San Francisco

RENO, NV, UNITED STATES, January 6, 2025 /⁨EINPresswire.com⁩/ -- Reno, NV – January 6, 2025 – Sarcomatrix Therapeutics, a pioneering biotech company advancing innovative therapies for muscle diseases, is proud to announce its participation in three high- …

Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...

Published on January 2, 2025 - 21:01 GMT

Sarcomatrix Therapeutics Strengthens Leadership Team with Appointment of Al Swarts as Chief of Technical Operations

RENO, NV, UNITED STATES, January 2, 2025 /⁨EINPresswire.com⁩/ -- Sarcomatrix Therapeutics Strengthens Leadership Team with Appointment of Al Swarts as Chief of Technical Operations Sarcomatrix Therapeutics, a biotechnology company focused on developing …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on September 27, 2024 - 15:09 GMT

Sarcomatrix Therapeutics Awarded Prestigious "Startup Spotlight" at BIO-Europe 2024

RENO, NV, UNITED STATES, September 27, 2024 /⁨EINPresswire.com⁩/ -- Sarcomatrix Therapeutics, an emerging leader in the development of innovative therapies for muscle diseases, is proud to announce that it has been awarded the highly coveted "Startup …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on September 20, 2024 - 17:56 GMT

Sarcomatrix has been crowned the Regional Champion of the Pegasus Startup World Cup Competition

Advances to Grand Finale for $1M Grand Prize in San Francisco RENO, NV, UNITED STATES, September 20, 2024 /⁨EINPresswire.com⁩/ -- Sarcomatrix, a pioneering leader in muscle disease therapy innovation, is proud to announce that it has been named the …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on September 9, 2024 - 20:34 GMT

Sarcomatrix Selected as One of 10 Companies to Present at Startup World Cup Regional, sponsored by Pegasus Tech Ventures

RENO, NV, UNITED STATES, September 9, 2024 /⁨EINPresswire.com⁩/ -- Sarcomatrix Therapeutics, a leading biotechnology company based in Northern Nevada, is proud to announce its selection as one of only 10 innovative companies to present at the prestigious …

Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...

Published on July 8, 2024 - 13:00 GMT

Sarcomatrix Therapeutics Secures Exclusive License Rights for Groundbreaking Muscle-Stabilizing and Regenerating Drugs

Innovative Treatments Targeting Muscular Dystrophies, Cachexia, and Sarcopenia to Transform the Future of Muscle-Wasting Disease Therapy RENO, NV, UNITED STATES, July 8, 2024 /⁨EINPresswire.com⁩/ -- Sarcomatrix Therapeutics Corp., a pioneering biotech …

Distribution channels: Banking, Finance & Investment Industry, Companies ...

Published on May 28, 2024 - 13:00 GMT

Sarcomatrix selected for an Oral Presentation at BIO International

RENO, NV, UNITED STATES, May 28, 2024 /⁨EINPresswire.com⁩/ -- Sarcomatrix, a pioneering biotechnology company dedicated to advancing solutions for muscle diseases, was selected for an Oral Presentation at Theater 1 on Wednesday, June 5, at 2:45:00 PM at …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on May 23, 2024 - 13:45 GMT

Sarcomatrix to Attend CureDuchenne FUTURES Conference 2024

RENO, NV, UNITED STATES, May 23, 2024 /⁨EINPresswire.com⁩/ -- Sarcomatrix Therapeutics Corp. is thrilled to announce its participation in the upcoming CureDuchenne FUTURES National Conference, taking place from May 23 to May 26, 2024, at the JW Marriott …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on May 13, 2024 - 22:41 GMT

Sarcomatrix Advances Lead Compound S-969 to Large Animal Studies for Muscular Dystrophy

RENO, NV, UNITED STATES, May 13, 2024 /⁨EINPresswire.com⁩/ -- Sarcomatrix, a pioneering company in the development of innovative treatments for muscular dystrophies and other genetic disorders, proudly announces the advancement of its lead compound, S-969 …

Distribution channels: Banking, Finance & Investment Industry, Companies ...

Published on May 13, 2024 - 13:00 GMT

Sarcomatrix Demonstrates Commitment to Diversity and Inclusion in Its Mission to Transform Muscle Disease Treatment

Diversity is the magic. The greater the diversity, the greater the perfection. RENO, NV, UNITED STATES, May 13, 2024 /⁨EINPresswire.com⁩/ -- Sarcomatrix, a pioneering biotechnology company dedicated to developing first-in-class therapies for muscle …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on May 10, 2024 - 14:15 GMT

Sarcomatrix Acquires Recombinant Human Laminin-111: A Promising Candidate for Treating LAMA2-RD Muscular Dystrophies

Recombinant human laminin-111, often referred to as rLaminin-111, mimics the natural laminin-alpha-2 protein found in healthy muscle tissue. RENO, NV, UNITED STATES, May 10, 2024 /⁨EINPresswire.com⁩/ -- Sarcomatrix Therapeutics Corp., a leader in …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on May 9, 2024 - 14:30 GMT

Boy Receives Experimental Therapy for Duchenne Muscular Dystrophy, Passes Away

Call to action, continue investing in a broad range of potential therapies to treat all forms of muscular dystrophy. RENO, NV, UNITED STATES, May 9, 2024 /⁨EINPresswire.com⁩/ -- A tragic incident has occurred in a clinical trial for Duchenne muscular …

Distribution channels: Business & Economy, Companies ...